Target intelligence / Profile preview

CDK-activating kinase assembly factor MAT1 (MAT1)

Target
MAT1
Molecular classification
Enzyme (specifically, assembly factor for kinase enzyme complex), Transcription regulation complex component, Other (RING finger protein)
01

Overview

CDK-activating kinase assembly factor MAT1 (also known as MNAT1) is an essential protein component of the CDK-activating kinase (CAK) complex, which also includes cyclin H and CDK7[1][2][3]. MAT1 stabilizes the interaction between CDK7 and cyclin H, forming a heterotrimeric complex fundamental for both cell cycle progression and transcription initiation by RNA polymerase II[2][3]. Within the CAK complex, MAT1 enhances the kinase’s ability to phosphorylate CDKs and the C-terminal domain (CTD) of RNA polymerase II, thereby regulating entry into cell cycle and transcriptional activity[1][2][3]. CAK, and specifically the MAT1 subunit, has gained therapeutic interest, particularly for targeting cancers highly dependent on transcriptional regulation; small molecule inhibitors such as THZ1 covalently inhibit CDK7 activity within CAK[2][3]. Defects or dysregulation in MAT1-containing complexes are linked to diseases including cancer and Cockayne syndrome[1].

Other names
MNAT1CAP35RNF66p35p36TFB3Menage a trois 1 (CAK assembly factor)RING finger protein MAT1Cyclin-G1-interacting proteinCyclin H assembly factorCDK-activating kinase assembly factorCyclin G1 interacting proteinMenage a trois-like protein 1
02

Mechanism of action

Irreversible inhibition of kinase activity (by targeting CDK7 active site, e.g., THZ1) Disruption of cell cycle progression and transcription by RNA polymerase II

03

Biological functions

Cell cycle controlActivation of cyclin-dependent kinases (CDK1, CDK2, CDK4, CDK6)RNA polymerase II transcription initiationCell proliferationSignal transduction
04

Disease associations

CancerCockayne syndromeOther diseases related to transcription and cell cycle dysregulation
05

Safety considerations

Potential for off-target effects due to similarity with other CDK-activating kinases (e.g., CDK12, CDK13)Possible impact on normal proliferative tissues due to central role in transcription and cell cycle regulation
06

Interacting drugs

THZ1

1 more in the full profile.

07

Biomarkers

High expression or dysregulation in cancers (especially those reliant on high transcription such as triple-negative breast cancer)Not established as a routine clinical biomarker for patient selection; currently under investigation in research settings

Beyond the preview

Go deeper on CDK-activating kinase assembly factor MAT1 (MAT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDK-activating kinase assembly factor MAT1 (MAT1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call